Wire · opportunities
M42 and Inocras Announce Strategic Collaboration to Advance Earlier Detection of Cancer ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 October 2026 · Fusion42 review
M42 and Inocras have partnered to deploy the MRDVision™ platform in the UAE for early detection of cancer recurrence via blood-based genomic profiling, starting with a pilot for high-risk breast cancer patients at Cleveland Clinic Abu Dhabi. This initiative aims to create local evidence on the clinical and health-economic benefits of MRD testing and to integrate this technology into UAE healthcare.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You can now plan to offer earlier cancer recurrence detection services using blood-based genomics within the UAE healthcare system. This opens a concrete opportunity to collaborate with regional hospital networks and integrate cutting-edge MRD testing in your clinical workflows.
◆ Coverage
1 source · 23 Oct 2026
◆ Related on Wire
◆ Topics